Published: May 8, 2026 at 9:40 am
A listed HealthTech has requested the suspension of trading in its shares after failing to secure new funding.
Trellus Health plc said it had managed to extend its cash runway into mid-June 2026 through cost-saving measures including further reductions in compensation and the renegotiation of vendor contracts.
It had previously reduced its monthly cash burn to an average of $300k and secured an emergency loan from one of its co-founders.
The board has engaged corporate restructuring advisers to protect stakeholders’ interests, and the board is now evaluating all options including the sale of Trellus Health Inc., the company’s US subsidiary.